Abstract
Our results suggested that emodin has potential anti-tumor effect on pancreatic cancer via its dual role in the promotion of apoptosis and suppression of angiogenesis, probably through regulating the expression of NF-κB and NF-κB-regulated angiogenesis-associated factors.
Introduction
Pancreatic cancer remains one of the most lethal malignancies worldwide, characterized by rapid progression, extensive vascularization, and a high degree of resistance to standard chemotherapeutic agents like gemcitabine. A primary driver of this aggressive phenotype is the constitutive activation of Nuclear Factor-kappa B (NF-κB). This protein complex acts as a master transcriptional regulator, promoting cell survival by inhibiting apoptosis and facilitating the growth of new blood vessels (angiogenesis).
Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a natural compound extracted from the root of rhubarb (Rheum palmatum L.), has previously shown promise in inducing apoptosis in various cancer types. However, its specific impact on the tumor microenvironment—particularly angiogenesis—and the underlying molecular mechanisms in complex in vivo systems have remained poorly understood. This study investigates whether emodin can effectively inhibit angiogenesis in pancreatic cancer by targeting the NF-κB signaling pathway.
Methodology
The research utilized a multi-faceted approach combining in vitro cell assays and an advanced in vivo orthotopic mouse model:
- Cellular Models: Human pancreatic cancer cell lines (SW1990 and Panc-1) and normal epithelial cells (HPNE) were used to evaluate toxicity and apoptosis via CCK-8 assays and flow cytometry.
- Angiogenesis Assays: A Matrigel tube formation assay was employed to assess the ability of cancer-derived endothelial cells to form vessel-like structures under the influence of emodin.
- Orthotopic Mouse Model: To simulate the human disease environment accurately, tumors were implanted directly into the pancreases of 48 nude mice, rather than using traditional subcutaneous models.
- Functional Imaging: The study employed MicroPET imaging (using $^{18}$F-FDG) to monitor tumor metabolism and X-ray vascular imaging to quantify blood vessel density in live animals.
- Molecular Analysis: Electrophoretic Mobility Shift Assays (EMSA) were used to determine NF-κB DNA-binding activity. Western blotting and RT-PCR quantified the expression of key angiogenesis-associated factors, including VEGF, MMP-2, MMP-9, and eNOS.
Key Results and Insights
Synergistic Tumor Inhibition
The most striking finding was the potent synergy between emodin and gemcitabine. In the orthotopic model, the combination therapy reduced tumor weight by approximately 77% compared to the control group (0.393g vs. 1.721g). This reduction was significantly greater than that achieved by either drug alone.
Metabolic and Vascular Suppression
Functional imaging provided clear evidence of emodin's impact:
- MicroPET: Treated tumors showed a significant decrease in the tumor-to-normal tissue (T/NT) uptake ratio of $^{18}$F-FDG, indicating a marked reduction in metabolic activity.
- Vascular Density: X-ray imaging and immunohistochemical staining (CD31 and CD105) confirmed a dramatic decrease in blood vessel distribution within the tumors, validating emodin's anti-angiogenic properties.
The NF-κB Hub
The study identified NF-κB as the central molecular target. Emodin effectively inhibited the DNA-binding activity of NF-κB, which in turn downregulated the expression of several downstream pro-angiogenic factors:
- VEGF (Vascular Endothelial Growth Factor): A primary driver of vessel growth.
- MMP-2 and MMP-9: Enzymes that degrade the extracellular matrix to allow for vessel expansion.
- eNOS Phosphorylation: A critical step in maintaining vascular tone and growth.
Interestingly, while emodin reduced these ligands, it did not affect the expression of VEGFR receptors, suggesting a specific interference with the signaling production rather than reception.
Discussion: Overcoming Chemoresistance
A significant hurdle in treating pancreatic cancer is that gemcitabine can paradoxically increase NF-κB activity, leading to acquired drug resistance. This study demonstrates that emodin can counteract this effect, "re-sensitizing" the tumor to chemotherapy. By simultaneously triggering apoptosis and "starving" the tumor of its blood supply, emodin provides a dual-action therapeutic strategy.
Conclusion and Future Directions
While these results are promising, several challenges remain before clinical application. The bioavailability and metabolic stability of emodin as a natural plant extract need optimization for human delivery. Furthermore, human pancreatic tumors often possess a dense, fibrous stroma that can impede drug penetration—a factor that requires further study in more complex models. Future research should also aim to pinpoint the exact "upstream" mechanism by which emodin prevents NF-κB activation, such as potential inhibition of IκB kinase (IKK). Ultimately, moving toward human clinical trials is the necessary step to confirm the safety and efficacy of emodin as a component of combination therapy for pancreatic cancer.
Summary updated